Nivolumab: beside a new treatment under test
581 studies: a new drug, cell therapy or vaccine is what the study tests. Page 6 of 6. Open to participants first (106), then studies with results posted, then the rest; newest registration first within each.
- Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal CancerWithdrawnNCT03575234Phase 1How we knowReport a problem
- A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid TumorsCompletedNCT03565445Phase 1How we knowReport a problem
- A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaTerminatedNCT03565406Phase 1How we knowReport a problem
- Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.Status unknownNCT03544723Phase 2How we knowReport a problem
- Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant MelanomaActive, not recruitingNCT03543969Early Phase 1How we knowReport a problem
- Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerCompletedNCT03532217Phase 1How we knowReport a problem
- A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous LymphocytesTerminatedNCT03526185Early Phase 1How we knowReport a problem
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedNCT03520686Phase 3How we knowReport a problem
- Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder CancerTerminatedNCT03518320Phase 1How we knowReport a problem
- Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid TumorsTerminatedNCT03511222Phase 1How we knowReport a problem
- Combined Immunotherapy and Radiosurgery for Metastatic Colorectal CancerCompletedNCT03507699Phase 1How we knowReport a problem
- A Study of Zolbetuximab (IMAB362) in Adults With Gastric CancerActive, not recruitingNCT03505320Phase 2How we knowReport a problem
- TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)CompletedNCT03475134Phase 1How we knowReport a problem
- LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasActive, not recruitingNCT03449108Phase 2How we knowReport a problem
- An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be RemovedTerminatedNCT03444753Phase 1How we knowReport a problem
- Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for CancerCompletedNCT03431948Phase 1How we knowReport a problem
- Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV MelanomaTerminatedNCT03425461Phase 1How we knowReport a problem
- CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With SarcomaCompletedNCT03425279Phase 1/2How we knowReport a problem
- Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaTerminatedNCT03422094Phase 1How we knowReport a problem
- An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung CancerWithdrawnNCT03417037Phase 3How we knowReport a problem
- A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic CancerCompletedNCT03396211Phase 1How we knowReport a problem
- An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and NeckWithdrawnNCT03386838Phase 3How we knowReport a problem
- VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal CancerCompletedNCT03373188Phase 1How we knowReport a problem
- Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLCCompletedNCT03326752Phase 1How we knowReport a problem
- Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2How we knowReport a problem
- A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingNCT03282344Phase 2How we knowReport a problem
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2How we knowReport a problem
- A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid TumorsCompletedNCT03203876Phase 1How we knowReport a problem
- A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced TumorsCompletedNCT03192943Phase 1How we knowReport a problem
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnNCT03169777Phase 1/2How we knowReport a problem
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03169764Phase 1/2How we knowReport a problem
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnNCT03169738Phase 1/2How we knowReport a problem
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03167177Phase 1/2How we knowReport a problem
- Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsActive, not recruitingNCT03155061Phase 1How we knowReport a problem
- Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCCompletedNCT03136627Phase 1/2How we knowReport a problem
- Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular LymphomaTerminatedNCT03121677Phase 1How we knowReport a problem
- A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid TumorsTerminatedNCT03119428Phase 1How we knowReport a problem
- CBP501, Cisplatin and Nivolumab in Advanced Refractory TumorsCompletedNCT03113188Phase 1How we knowReport a problem
- Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginTerminatedNCT03100006Phase 1/2How we knowReport a problem
- Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular CarcinomaTerminatedNCT03059147Phase 1How we knowReport a problem
- Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal CancerTerminatedNCT02991196Phase 1How we knowReport a problem
- Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV MelanomaCompletedNCT02983006Phase 1How we knowReport a problem
- Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)CompletedNCT02973113Phase 1How we knowReport a problem
- Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid TumorsCompletedNCT02966548Phase 1How we knowReport a problem
- CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck CancerActive, not recruitingNCT02955290Phase 1/2How we knowReport a problem
- A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid TumorsCompletedNCT02955251Phase 1How we knowReport a problem
- Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung CancerCompletedNCT02947386Phase 1How we knowReport a problem
- Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02944396Phase 1How we knowReport a problem
- Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and NivolumabCompletedNCT02935790Phase 1How we knowReport a problem
- Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung CancerWithdrawnNCT02924233Phase 1/2How we knowReport a problem
- A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder CancerCompletedNCT02897765Phase 1How we knowReport a problem
- Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis FungoidesTerminatedNCT02890368Phase 1How we knowReport a problem
- Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the BladderActive, not recruitingNCT02845323Phase 2How we knowReport a problem
- Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell CancerTerminatedNCT02842125Phase 1/2How we knowReport a problem
- A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung CancerCompletedNCT02840994Phase 1How we knowReport a problem
- Exploratory Study of BO-112 in Adult Patients With Aggressive Solid TumorsCompletedNCT02828098Phase 1How we knowReport a problem
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)Active, not recruitingNCT02817633Phase 1How we knowReport a problem
- Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02812667Phase 1How we knowReport a problem
- Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1CompletedNCT02775292Phase 1How we knowReport a problem
- A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian CancerCompletedNCT02737787Phase 1How we knowReport a problem
- Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)CompletedNCT02658981Phase 1How we knowReport a problem
- Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic MelanomaCompletedNCT02652455Early Phase 1How we knowReport a problem
- Vigil™ + Nivolumab in Advanced Non-Small Cell Lung CancerWithdrawnNCT02639234Phase 2How we knowReport a problem
- A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Status unknownNCT02637531Phase 1How we knowReport a problem
- Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial TumorsCompletedNCT02636036Phase 1How we knowReport a problem
- Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung CancerTerminatedNCT02635061Phase 1How we knowReport a problem
- Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or NivolumabCompletedNCT02628574Phase 1How we knowReport a problem
- Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant TumorsCompletedNCT02534506Phase 1How we knowReport a problem
- A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and NivolumabCompletedNCT02518958Phase 1How we knowReport a problem
- A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced CancerCompletedNCT02483247Phase 1How we knowReport a problem
- Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid TumorsCompletedNCT02476123Phase 1How we knowReport a problem
- A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced CancersCompletedNCT02467361Phase 1How we knowReport a problem
- Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the LungWithdrawnNCT02466568Phase 1/2How we knowReport a problem
- Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerActive, not recruitingNCT02453620Phase 1How we knowReport a problem
- In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®CompletedNCT02423863Phase 2How we knowReport a problem
- Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesTerminatedNCT02419495Phase 1How we knowReport a problem
- HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIACompletedNCT02379520Phase 1How we knowReport a problem
- A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid TumorsCompletedNCT02335918Phase 1/2How we knowReport a problem
- A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)Active, not recruitingNCT02293980Phase 1How we knowReport a problem
- A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus NivolumabTerminatedNCT02124850Phase 1How we knowReport a problem
- A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsActive, not recruitingNCT02099058Phase 1How we knowReport a problem